COMP <GO>
SRPT vs ABBV // DIVIDEND YIELD & FCF PAYOUT SAFETY
Sarepta Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SRPT 1
— ABBV 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABBV
LAST: $19.23 (-0.47%) • MKT CAP: $2.03B
dividend-safety
0.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
dividend-safety
2.27%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRPT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRPT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | SRPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.14% | 3.47% | -18.61 | ABBV | /fcf-yield <GO> |
| Operating Margin | -37.50% | 24.60% | -62.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -38.30% | 6.90% | -45.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 8.60% | -4.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 65.1 | -13.89 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.03B | $513.86B | -$511.83B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRPT REV | ABBV REV | SRPT GROSS % | ABBV GROSS % | SRPT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.86B | $61.16B | 98.0% | 70.2% | -$307.5M | $17.82B |
| FY 2024 | $1.79B | $56.33B | — | 70.0% | -$342.7M | $17.83B |
| FY 2023 | $1.14B | $54.32B | — | — | -$501.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRPT // BETA —
ABBV // BETA 1.15